SCHEMBL24926544

SCHEMBL24926544

Cc1c(C(=O)Oc2ccccc2)c(O)c(I)c(Br)c1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.38
MAPT P10636 9/20 0.37
RAB9A P51151 3/20 0.37
NPSR1 Q6W5P4 2/20 0.37
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
SOS1 Q07889 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
ATM Q13315 1/20 0.33
MAOB P27338 1/20 0.33
POLB P06746 1/20 0.33
NPC1 O15118 2/20 0.33
PTK2B Q14289 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
KMT2A Q03164 2/20 0.32
LMNA P02545 1/20 0.32
TP53 P04637 1/20 0.32
CYP3A4 P08684 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24926538 0.83 PTPN1 (0.39) HPGDHSD17B10MAOBLMNA
SCHEMBL15521295 0.83 NSD2 (0.36) NSD2MAPTRAB9ANPSR1HPGD
SCHEMBL20860398 0.75 NSD2 (0.38) NSD2MAPTRAB9ANPSR1HPGD
SCHEMBL9282979 0.75 NSD2 (0.42) NSD2MAPTRAB9ANPSR1HPGD
SCHEMBL114127 0.71 NSD2 (0.48) NSD2MAPTRAB9ANPSR1HPGD
SCHEMBL12108786 0.71 NSD2 (0.41) NSD2MAPTRAB9ANPSR1HPGD
SCHEMBL17635803 0.70 NSD2 (0.46) NSD2MAPTRAB9ANPSR1HPGD
SCHEMBL12108764 0.70 PTPN1 (0.38) HPGDHSD17B10MAOBLMNA
SCHEMBL1534079 0.69 HSD17B10 (0.44) NSD2MAPTRAB9ANPSR1HPGD
SCHEMBL12111118 0.69 FAAH (0.36) L3MBTL1NPC1KMT2ALMNACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230031954-A1 TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT TETRAPHASE PHARMACEUTICALS, INC. 2023-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230031954-A1 TETRACYCLINE COMPOUNDS AND METHODS OF TREATMENT MCL1, ABL1, MALT1 NSD2 287/4885MAPT 2198/4885RAB9A 2103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.